Bristol-Myers Squibb Company (BMY)
2 Beaten-Down Dividend Stocks to Buy and Hold
They're down, but they aren't out, at least not in the eyes of patient investors.
Bristol-Myers Squibb's $14 Billion Potential - Analyst Upgrades Stock
Leerink Partners has upgraded Bristol-Myers Squibb & Co BMY, stating that the company enters a catalyst-rich period in 2025-2027 beyond Cobenfy (a schizophrenia drug) and milvexian (anticoagulant).
Buy, Sell, Or Hold BMY Stock?
Bristol Myers Squibb stock (NYSE: BMY) was up 10% on Monday, November 11, after its peer AbbVie (NYSE; ABBV) announced that two of its mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year.
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, Global Drug Development Robert Plenge - EVP, Chief Research Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez Okay. So, in the interest of staying on time here, really pleased to have Bristol Myers Squibb joining us.
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
BMY has been having a good run for the past three months. The stock recently touched a 52-week high.
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.
What's Next For BMY Stock After An Upbeat Q3?
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings of $1.80 per share, compared to the consensus estimates of $11.3 billion and $1.49, respectively.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors' attention was on technology stocks. But that means you may have overlooked two biopharmaceutical companies that delivered solid earnings reports.
5 Must Own High-Yield Dividend Stocks If Kamala Harris Wins
24/7 Wall St. Insights The seemingly endless political season is almost over.
Stock Market Rally Is 2 Years Old: 3 Passive Income Favorites Are November Bargains
24/7 Wall St. Insights The long AI-driven rally has many tech stocks overvalued.
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.
